These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 31845794)

  • 1. Novel HDAC6 Inhibitors Increase Tubulin Acetylation and Rescue Axonal Transport of Mitochondria in a Model of Charcot-Marie-Tooth Type 2F.
    Adalbert R; Kaieda A; Antoniou C; Loreto A; Yang X; Gilley J; Hoshino T; Uga K; Makhija MT; Coleman MP
    ACS Chem Neurosci; 2020 Feb; 11(3):258-267. PubMed ID: 31845794
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bicyclic-Capped Histone Deacetylase 6 Inhibitors with Improved Activity in a Model of Axonal Charcot-Marie-Tooth Disease.
    Shen S; Benoy V; Bergman JA; Kalin JH; Frojuello M; Vistoli G; Haeck W; Van Den Bosch L; Kozikowski AP
    ACS Chem Neurosci; 2016 Feb; 7(2):240-58. PubMed ID: 26599234
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HDAC6 inhibitors reverse axonal loss in a mouse model of mutant HSPB1-induced Charcot-Marie-Tooth disease.
    d'Ydewalle C; Krishnan J; Chiheb DM; Van Damme P; Irobi J; Kozikowski AP; Vanden Berghe P; Timmerman V; Robberecht W; Van Den Bosch L
    Nat Med; 2011 Jul; 17(8):968-74. PubMed ID: 21785432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of Improved HDAC6 Inhibitors as Pharmacological Therapy for Axonal Charcot-Marie-Tooth Disease.
    Benoy V; Vanden Berghe P; Jarpe M; Van Damme P; Robberecht W; Van Den Bosch L
    Neurotherapeutics; 2017 Apr; 14(2):417-428. PubMed ID: 27957719
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HDAC6 inhibition promotes α-tubulin acetylation and ameliorates CMT2A peripheral neuropathy in mice.
    Picci C; Wong VSC; Costa CJ; McKinnon MC; Goldberg DC; Swift M; Alam NM; Prusky GT; Shen S; Kozikowski AP; Willis DE; Langley B
    Exp Neurol; 2020 Jun; 328():113281. PubMed ID: 32147437
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HDAC6 is a therapeutic target in mutant GARS-induced Charcot-Marie-Tooth disease.
    Benoy V; Van Helleputte L; Prior R; d'Ydewalle C; Haeck W; Geens N; Scheveneels W; Schevenels B; Cader MZ; Talbot K; Kozikowski AP; Vanden Berghe P; Van Damme P; Robberecht W; Van Den Bosch L
    Brain; 2018 Mar; 141(3):673-687. PubMed ID: 29415205
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aberrant GlyRS-HDAC6 interaction linked to axonal transport deficits in Charcot-Marie-Tooth neuropathy.
    Mo Z; Zhao X; Liu H; Hu Q; Chen XQ; Pham J; Wei N; Liu Z; Zhou J; Burgess RW; Pfaff SL; Caskey CT; Wu C; Bai G; Yang XL
    Nat Commun; 2018 Mar; 9(1):1007. PubMed ID: 29520015
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rutin increases alpha-tubulin acetylation via histone deacetylase 6 inhibition.
    Çetin Ö; Sari S; Erdem-Yurter H; Bora G
    Drug Dev Res; 2022 Jun; 83(4):993-1002. PubMed ID: 35266183
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MeCP2 deficiency is associated with reduced levels of tubulin acetylation and can be restored using HDAC6 inhibitors.
    Gold WA; Lacina TA; Cantrill LC; Christodoulou J
    J Mol Med (Berl); 2015 Jan; 93(1):63-72. PubMed ID: 25209898
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of HDAC6 deacetylase activity increases its binding with microtubules and suppresses microtubule dynamic instability in MCF-7 cells.
    Asthana J; Kapoor S; Mohan R; Panda D
    J Biol Chem; 2013 Aug; 288(31):22516-26. PubMed ID: 23798680
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of histone deacetylase 6 (HDAC6) protects against vincristine-induced peripheral neuropathies and inhibits tumor growth.
    Van Helleputte L; Kater M; Cook DP; Eykens C; Rossaert E; Haeck W; Jaspers T; Geens N; Vanden Berghe P; Gysemans C; Mathieu C; Robberecht W; Van Damme P; Cavaletti G; Jarpe M; Van Den Bosch L
    Neurobiol Dis; 2018 Mar; 111():59-69. PubMed ID: 29197621
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HDAC6 inhibitor blocks amyloid beta-induced impairment of mitochondrial transport in hippocampal neurons.
    Kim C; Choi H; Jung ES; Lee W; Oh S; Jeon NL; Mook-Jung I
    PLoS One; 2012; 7(8):e42983. PubMed ID: 22937007
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuronal complexity is attenuated in preclinical models of migraine and restored by HDAC6 inhibition.
    Bertels Z; Singh H; Dripps I; Siegersma K; Tipton AF; Witkowski WD; Sheets Z; Shah P; Conway C; Mangutov E; Ao M; Petukhova V; Karumudi B; Petukhov PA; Baca SM; Rasenick MM; Pradhan AA
    Elife; 2021 Apr; 10():. PubMed ID: 33856345
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tetrahydroquinoline-Capped Histone Deacetylase 6 Inhibitor SW-101 Ameliorates Pathological Phenotypes in a Charcot-Marie-Tooth Type 2A Mouse Model.
    Shen S; Picci C; Ustinova K; Benoy V; Kutil Z; Zhang G; Tavares MT; Pavlíček J; Zimprich CA; Robers MB; Van Den Bosch L; Bařinka C; Langley B; Kozikowski AP
    J Med Chem; 2021 Apr; 64(8):4810-4840. PubMed ID: 33830764
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HDAC6 regulates mitochondrial transport in hippocampal neurons.
    Chen S; Owens GC; Makarenkova H; Edelman DB
    PLoS One; 2010 May; 5(5):e10848. PubMed ID: 20520769
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HDAC6 inhibitors: Translating genetic and molecular insights into a therapy for axonal CMT.
    Rossaert E; Van Den Bosch L
    Brain Res; 2020 Apr; 1733():146692. PubMed ID: 32006555
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel orally active HDAC6 inhibitor T-518 shows a therapeutic potential for Alzheimer's disease and tauopathy in mice.
    Onishi T; Maeda R; Terada M; Sato S; Fujii T; Ito M; Hashikami K; Kawamoto T; Tanaka M
    Sci Rep; 2021 Jul; 11(1):15423. PubMed ID: 34326423
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective HDAC6 inhibition prevents TNF-α-induced lung endothelial cell barrier disruption and endotoxin-induced pulmonary edema.
    Yu J; Ma Z; Shetty S; Ma M; Fu J
    Am J Physiol Lung Cell Mol Physiol; 2016 Jul; 311(1):L39-47. PubMed ID: 27190059
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased acetylation of Peroxiredoxin1 by HDAC6 inhibition leads to recovery of Aβ-induced impaired axonal transport.
    Choi H; Kim HJ; Kim J; Kim S; Yang J; Lee W; Park Y; Hyeon SJ; Lee DS; Ryu H; Chung J; Mook-Jung I
    Mol Neurodegener; 2017 Feb; 12(1):23. PubMed ID: 28241840
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HDAC6 inhibition results in tau acetylation and modulates tau phosphorylation and degradation in oligodendrocytes.
    Noack M; Leyk J; Richter-Landsberg C
    Glia; 2014 Apr; 62(4):535-47. PubMed ID: 24464872
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.